AL Amyloidosis Clinical Trials

30 recruitingLast updated: June 18, 2026

There are 30 actively recruiting al amyloidosis clinical trials across 15 countries. Studies span Phase 2, Phase 1, Not Applicable, Early Phase 1, Phase 3. Top locations include Pavia, Italy, Boston, Massachusetts, United States, Rochester, Minnesota, United States. Updated daily from ClinicalTrials.gov.


AL Amyloidosis Trials at a Glance

30 actively recruiting trials for al amyloidosis are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 2 with 10 trials, with the heaviest enrollment activity in Pavia, Boston, and Rochester. Lead sponsors running al amyloidosis studies include Fondazione IRCCS Policlinico San Matteo di Pavia, Peking Union Medical College Hospital, and Peking University People's Hospital.

Browse al amyloidosis trials by phase

Treatments under study

About AL Amyloidosis Clinical Trials

Looking for clinical trials for AL Amyloidosis? There are currently 23 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new AL Amyloidosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about AL Amyloidosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 30 trials

Recruiting
Phase 2

A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

Multiple MyelomaAL Amyloidosis
Shanghai Zhongshan Hospital30 enrolled1 locationNCT07638683
Recruiting
Early Phase 1

Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis

AL AmyloidosisSystemic Light Chain AmyloidosisRelapsed/Refractory Light Chain Amyloidosis
Beijing Boren Hospital30 enrolled1 locationNCT07626476
Recruiting
Phase 3

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

AL Amyloidosis
SWOG Cancer Research Network338 enrolled117 locationsNCT06022939
Recruiting
Phase 1Phase 2

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

AmyloidosisAL Amyloidosis
University of Texas Southwestern Medical Center37 enrolled3 locationsNCT05145816
Recruiting

One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS

Multiple MyelomaAL AmyloidosisPOEMS Syndrome
Fondazione IRCCS Policlinico San Matteo di Pavia100 enrolled1 locationNCT07448935
Recruiting
Phase 1

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Relapsed/Refractory AL Amyloidosis
Gracell Biotechnologies (Shanghai) Co., Ltd.9 enrolled9 locationsNCT07250269
Recruiting
Phase 2

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

AL Amyloidosis
European Myeloma Network B.V.30 enrolled10 locationsNCT06649695
Recruiting

A Registry of AL Amyloidosis (ReAL)

AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia5,000 enrolled1 locationNCT04839003
Recruiting

Promoting Diagnosis and Management of AL in Italy (ProDigALIty)

Monoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple MyelomaAL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia760 enrolled4 locationsNCT06383143
Recruiting

A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)

AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia400 enrolled6 locationsNCT06205953
Recruiting
Phase 1

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Refractory AL AmyloidosisRecurrent AL Amyloidosis
National Cancer Institute (NCI)24 enrolled16 locationsNCT04847453
Recruiting
Phase 2

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

AL Amyloidosis
Mayo Clinic96 enrolled2 locationsNCT05898646
Recruiting
Phase 1Phase 2

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

AmyloidosisLight Chain AmyloidosisRelapsed AL Amyloidosis+1 more
Alexion Pharmaceuticals, Inc.91 enrolled18 locationsNCT07081646
Recruiting

Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource

Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceAL Amyloidosis+1 more
Ohio State University Comprehensive Cancer Center5,000 enrolled1 locationNCT01408225
Recruiting

Rapid dFLC Response Predict CHR in AL Amyloidosis

Systemic AL Amyloidosis
Peking University People's Hospital50 enrolled8 locationsNCT06627309
Recruiting
Not Applicable

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

AL AmyloidosisAmyloidosis; Systemic
Jin Lu, MD41 enrolled6 locationsNCT06192979
Recruiting
Phase 1Phase 2

Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

AL Amyloidosis
Brigham and Women's Hospital49 enrolled1 locationNCT06569147
Recruiting

Investigating the Pathogenic Role of N-glycosylation in AL Amyloidosis: Molecular Bases, Diagnosis, and Treatment

Multiple MyelomaMGUSAL Amyloidosis+1 more
Fondazione IRCCS Policlinico San Matteo di Pavia100 enrolled1 locationNCT07448779
Recruiting

BE.Amycon Biobank & Data Registry UZ Leuven

AmyloidosisAL AmyloidosisAmyloidosis Cardiac
Universitaire Ziekenhuizen KU Leuven505 enrolled2 locationsNCT07172243
Recruiting
Phase 3

Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

AL AmyloidosisCardiac AmyloidosisATTR Amyloidosis
Life Molecular Imaging GmbH200 enrolled14 locationsNCT05184088